A Phase II, randomised, multi-centre placebo-controlled, double-blind study to investigate the safety of GS-248, and efficacy on Raynaud's phenomenon (RP) and peripheral vascular blood flow in patients with systemic sclerosis (SSc)
Latest Information Update: 13 Aug 2024
At a glance
- Drugs Vipoglanstat (Primary)
- Indications Raynaud's disease; Systemic scleroderma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Gesynta Pharma
Most Recent Events
- 02 Aug 2022 Status changed from active, no longer recruiting to completed.
- 21 Jun 2022 This trial has been completed in Netherland, according to European Clinical Trials Database record.
- 15 Jun 2022 Status changed from recruiting to active, no longer recruiting.